MVIR:STO
Medivir AB
1,46 SEK
0,00%
(0,00) 1K
8-okt, 17:29:45 (GMT+2) · SEK
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoMVIR tikeri uchun statistika yaratilmoqda...
Bozor kapitali
908,95 mln
Oʻrtacha hajm
1,41 mln
Hajmi
0,00
52 haftalik eng yuqori
2,88 SEK
52 haftalik eng past
0,34 SEK
Aksiya boʻyicha daromad
-0,37 SEK
Muomaladagi aksiyalar
624,18 mln
Xodimlar soni
6
Bozor kapitali
908,95 mln
Oʻrtacha hajm
1,41 mln
Hajmi
0,00
52 haftalik eng yuqori
2,88 SEK
52 haftalik eng past
0,34 SEK
Aksiya boʻyicha daromad
-0,37 SEK
Muomaladagi aksiyalar
624,18 mln
Xodimlar soni
6
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance UK
·
1 soat oldin
Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company
Seeking Alpha
·
12 daqiqa oldin
Nasdaq CEO: Tokenization could unlock tens of billions in trapped capital
Simply Wall Street
·
16 daqiqa oldin
Intel (INTC) Deepens AI Chip R And D Partnership
Investor's Business Daily
·
3 soat oldin
Dow Jones Futures Rise After AI Stocks Tumble On OpenAI News; SpaceX Move Slams Verizon, AT&T Late
Profil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Medivir AB haqida